It’s a volatile time for biopharma, and a unique juncture in our industry’s history. War in Ukraine, a bearish market and supply chain chaos are just a few of the factors that kept much of the industry away from the table. Entering 2023, the investment and dealmaking panorama remains a puzzle. Despite worries and uncertainties, there are hints that dealmaking intensity may be poised for a rebound after a year of inertia that mirrored the slump in major biotech stock indexes. What lies ahead for dealmaking in the biopharmaceutical industry in 2023?
Our 13th Dealmakers’ Intentions Survey attempts to answer this question, based on responses from more than 100 members of the biopharma community, most of them with executive-level influence on decision making. This report, released recently at Biotech Showcase—an event co-located with the famous J.P. Morgan Healthcare Conference in San Francisco—captures their expectations for deal activity, supply and demand for specific assets and different development stages, pitfalls leading to failure and other factors affecting dealmaking.
Neel Patel, Executive Managing Director, Commercial Advisory Group at Syneos Health and lead author of the report, joins the podcast to discuss the industry’s first time back in person at J.P. Morgan in three years, as well as key findings from the survey.
Read the latest Dealmakers’ Intentions report here.
